BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sanofi readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sanofi's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07216079-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07216079)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Rilz
 abrutinib for the Adult Participants With Chronic ITP Who Have Completed P
 hase 3 Study in Japan\nEstimated primary completion: 25 November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07216079
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975722-9657@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SAR442970: Phase 2 readout est. (NCT06975722)
DESCRIPTION:SAR442970\, phase 2.\nStudy: A Study to Investigate the Efficac
 y and Safety of Brivekimig in Adult Participants With Ulcerative Colitis\n
 Estimated primary completion: 17 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06975722
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958536-9657@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SAR442970: Phase 2 readout est. (NCT06958536)
DESCRIPTION:SAR442970\, phase 2.\nStudy: A Study to Investigate Efficacy an
 d Safety of Brivekimig in Participants With Crohn's Disease\nEstimated pri
 mary completion: 17 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sar442970#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06958536
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500702-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:rilzabrutinib: Phase 2 readout est. (NCT06500702)
DESCRIPTION:rilzabrutinib\, phase 2.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Frexalimab\, Brivekimig\, or Rilzabrutinib in Participant
 s Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or M
 inimal Change Disease\nEstimated primary completion: 23 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06500702
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477704-1033@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:Praluent (Alirocumab): Phase 2 readout est. (NCT07477704)
DESCRIPTION:Praluent (Alirocumab)\, phase 2\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: A Study to See How Safe and Effective Alirocumab is Whe
 n Given Weekly to Adult Participants Who Have Hypercholesterolemia\nEstima
 ted primary completion: 29 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alirocumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07477704
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584670-2720@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Daxokafusp alfa: Phase 1/2 readout est. (NCT05584670)
DESCRIPTION:Daxokafusp alfa\, phase 1/2.\nStudy: A First-in-human\, Dose Es
 calation and Dose Expansion Study of SAR445877 in Adult Participants With 
 Advanced Solid Tumors\nEstimated primary completion: 19 January 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05584670
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170917-9657@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:SAR442970: Phase 2 readout est. (NCT07170917)
DESCRIPTION:SAR442970\, phase 2\, Hidradenitis Suppurativa.\nStudy: Briveki
 mig for the Treatment of Moderate to Severe Hidradenitis Suppurativa\nEsti
 mated primary completion: 9 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07170917
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984627-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:rilzabrutinib: Phase 2 readout est. (NCT06984627)
DESCRIPTION:rilzabrutinib\, phase 2.\nStudy: A Study to Investigate the Eff
 icacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disea
 se\nEstimated primary completion: 11 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06984627
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175038-545@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ROC-101: Phase 2 readout est. (NCT07175038)
DESCRIPTION:ROC-101\, phase 2\, Pulmonary Arterial Hypertension.\nStudy: A 
 Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) an
 d Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH
 ) (ROCSTAR STUDY)\nEstimated primary completion: March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/roc-101#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07175038
URL:https://assetmemo.bio/drug/roc-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05662319-10760@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Qfitlia (Fitusiran): Phase 3 readout est. (NCT05662319)
DESCRIPTION:Qfitlia (Fitusiran)\, phase 3.\nStudy: A Study to Test a Medici
 ne (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in
  Male Adolescent or Adult Participants With Severe Hemophilia\nEstimated p
 rimary completion: 25 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/fitusiran#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05662319
URL:https://assetmemo.bio/drug/fitusiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-3136@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib an
 d Dexamethasone in Adult Participants With Relapsed and/or Refractory Mult
 iple Myeloma\nEstimated primary completion: 1 April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3136@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Isatuximab: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156175-11338@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:SAR444336: Phase 2 readout est. (NCT07156175)
DESCRIPTION:SAR444336\, phase 2\, Microscopic Colitis.\nStudy: A Study to I
 nvestigate the Efficacy and Safety of SAR444336 in Adults With Microscopic
  Colitis in Clinical Remission\nEstimated primary completion: 8 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sar444336#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07156175
URL:https://assetmemo.bio/drug/sar444336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06111586-7194@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Frexalimab: Phase 2 readout est. (NCT06111586)
DESCRIPTION:Frexalimab\, phase 2.\nStudy: Frexalimab in Preservation of End
 ogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on
  Top of Insulin Therapy (FABULINUS)\nEstimated primary completion: 28 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/frexalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT061115
 86
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812988-9657@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:SAR442970: Phase 2 readout est. (NCT06812988)
DESCRIPTION:SAR442970\, phase 2.\nStudy: Treatment of Type 1 Diabetes With 
 Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecu
 le\nEstimated primary completion: 29 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06812988
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141473-7194@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141473)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms o
 f Multiple Sclerosis\nEstimated primary completion: 6 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06141473
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660667-5116@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:SAR402663: Phase 1/2 readout est. (NCT06660667)
DESCRIPTION:SAR402663\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovas
 cular Age-related Macular Degeneration\nEstimated primary completion: 18 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sar402663#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066606
 67
URL:https://assetmemo.bio/drug/sar402663#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263206-1356@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270602
DTEND;VALUE=DATE:20270603
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT05263206)
DESCRIPTION:Dupixent (dupilumab)\, phase 3.\nStudy: Efficacy and Safety of 
 Subcutaneous Dupilumab for the Treatment of Adult Participants With Chroni
 c Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)\nEstimated primary
  completion: 2 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05263206
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676319-1424@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06676319)
DESCRIPTION:lunsekimig\, phase 2\, Asthma.\nStudy: Study of Lunsekimig (SAR
 443765) Compared With Placebo in Adults With High-risk Asthma\nEstimated p
 rimary completion: 21 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lunsekimig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06676319
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06290141-11341@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Riliprubart: Phase 3 readout est. (NCT06290141)
DESCRIPTION:Riliprubart\, phase 3\, Chronic Inflammatory Demyelinating Poly
 neuropathy.\nStudy: A Study to Test the Efficacy and Safety of Riliprubart
  Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in Peopl
 e With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\nEstimated
  primary completion: 9 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/riliprubart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06290141
URL:https://assetmemo.bio/drug/riliprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325292-7194@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07325292)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Non-inferior
 ity Study of Frexalimab Subcutaneous Administration Compared to Intravenou
 s Administration in Adult Participants With Multiple Sclerosis\nEstimated 
 primary completion: 15 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/frexalimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07325292
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975865-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270723
DTEND;VALUE=DATE:20270724
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT06975865)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: The Efficacy and Safety of Ril
 zabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease\nE
 stimated primary completion: 23 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06975865
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-1886@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Belumosudil: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Belumosudil\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab 
 in Combination With Novel Agents in RRMM - Master Protocol\nEstimated prim
 ary completion: 13 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/belumosudil#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225569-11339@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270922
DTEND;VALUE=DATE:20270923
SUMMARY:SAR445399: Phase 2 readout est. (NCT07225569)
DESCRIPTION:SAR445399\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study
  to Investigate Efficacy and Safety With SAR445399 in Adult Participants W
 ith Moderate to Severe Hidradenitis Suppurativa\nEstimated primary complet
 ion: 22 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sar445399#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07225569
URL:https://assetmemo.bio/drug/sar445399#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215234-5224@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:SAR446597: Phase 1/2 readout est. (NCT07215234)
DESCRIPTION:SAR446597\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR
 446597 in Participants With Geographic Atrophy Secondary to Age-related Ma
 cular Degeneration\nEstimated primary completion: 13 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sar446597#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07215234
URL:https://assetmemo.bio/drug/sar446597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293053-1356@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06293053)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Prurigo Nodularis.\nStudy: A S
 tudy to Investigate the Pharmacokinetics and Safety of Dupilumab in Partic
 ipants ≥6 Months to <18 Years of Age With Prurigo Nodularis\nEstimated p
 rimary completion: 28 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06293053
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007962-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07007962)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With
  Immune Thrombocytopenia (ITP) Who Failed First-line Treatment\nEstimated 
 primary completion: 5 November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07007962
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02991469-5897@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Sarilumab: Phase 2 readout est. (NCT02991469)
DESCRIPTION:Sarilumab\, phase 2\, Systemic Juvenile Idiopathic Arthritis.\n
 Study: A Repeated Dose-finding Study of Sarilumab in Children and Adolesce
 nts With Systemic Juvenile Idiopathic Arthritis (SKYPS)\nEstimated primary
  completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02991469
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141486-7194@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141486)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Second
 ary Progressive Multiple Sclerosis\nEstimated primary completion: 24 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614148
 6
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-1356@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07919899)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: Pha
 rmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupilumab and Be
 rahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary completion:
  2 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupiluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 919899
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184996-1@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184996)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: An Induction 
 Study to Investigate the Efficacy and Safety of Duvakitug in Participants 
 With Moderately to Severely Active Ulcerative Colitis\nEstimated primary c
 ompletion: 9 May 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07184996
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086976-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07086976)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: A Study to Investigate the Eff
 icacy\, Safety\, and Pharmacokinetics of Oral Rilzabrutinib Compared With 
 Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hem
 olytic Anemia\nEstimated primary completion: 31 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07086976
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812116-1@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:duvakitug: Phase 2 readout est. (NCT07812116)
DESCRIPTION:duvakitug\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study
  to Investigate Efficacy and Safety of Duvakitug in Adult Participants Wit
 h Moderate to Severe Hidradenitis Suppurativa\nEstimated primary completio
 n: 16 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duva
 kitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07812116
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112378-1356@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07112378)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Eosinophilic Esophagitis.\nStu
 dy: A Study of Dupilumab in Small Children With an Allergic Condition of t
 he Esophagus (Food Pipe): Eosinophilic Esophagitis\nEstimated primary comp
 letion: 19 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07112378
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190196-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280628
DTEND;VALUE=DATE:20280629
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07190196)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: A 52-week Study of Rilzabrutin
 ib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-r
 elated Disease\nEstimated primary completion: 28 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07190196
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822790-1043@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06822790)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Hypertriglyceridemia.\nStudy:
  Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglycer
 idemia\nEstimated primary completion: July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/plozasiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06822790
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692204-2720@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280802
DTEND;VALUE=DATE:20280803
SUMMARY:Daxokafusp alfa: Phase 2 readout est. (NCT07692204)
DESCRIPTION:Daxokafusp alfa\, phase 2.\nStudy: A Dose Optimization/Expansio
 n Study of SAR445877 in Adult Chinese Participants With Advanced Gastric o
 r Gastroesophageal Junction Cancer\nEstimated primary completion: 2 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/daxokafusp-alf
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 692204
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185009-1@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:duvakitug: Phase 3 readout est. (NCT07185009)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: A Maintenance
  Study to Investigate the Efficacy and Safety of Duvakitug in Participants
  With Moderately to Severely Active Ulcerative Colitis\nEstimated primary 
 completion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/duvakitug#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185009
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116031-1886@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07116031)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: A St
 udy of Belumosudil in Children With Chronic Graft Versus Host Disease (sch
 oolROCK)\nEstimated primary completion: 25 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07116031
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143891-1886@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06143891)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Test an Oral Medicine\, Belumosudil\, in Combination With Corticost
 eroids in Participants at Least 12 Years of Age With Newly Diagnosed Chron
 ic Graft Versus Host Disease.\nEstimated primary completion: 29 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614389
 1
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704580-5897@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20281026
DTEND;VALUE=DATE:20281027
SUMMARY:Sarilumab: Phase 1/2 readout est. (NCT07704580)
DESCRIPTION:Sarilumab\, phase 1/2\, Rheumatoid Arthritis.\nStudy: Phase 1b/
 2 Study of IV Sarilumab in Adult With RA\nEstimated primary completion: 26
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704580
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3136@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: International 
 Treatment-extension Study in Adult Participants With Multiple Myeloma and 
 Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary compl
 etion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05669989
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191315-1356@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06191315)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Asthma.\nStudy: Efficacy and S
 afety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Whee
 ze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)\nEstimated primary completi
 on: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06191315
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082037-1886@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06082037)
DESCRIPTION:Belumosudil\, phase 3.\nStudy: A Study to Test How Effective Be
 lumosudil Tablets Are for Treating Adult Participants With Chronic Lung Al
 lograft Dysfunction\nEstimated primary completion: 29 January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06082037
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914908-1424@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290222
DTEND;VALUE=DATE:20290223
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06914908)
DESCRIPTION:lunsekimig\, phase 2.\nStudy: Long-term Safety and Efficacy Eva
 luation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis Wi
 th Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinic
 al Study\nEstimated primary completion: 22 February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06914908
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844214-11342@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SAR446268: Phase 1/2 readout est. (NCT06844214)
DESCRIPTION:SAR446268\, phase 1/2\, Myotonic Dystrophy Type 1.\nStudy: A St
 udy to Investigate the Safety\, Tolerability\, and Efficacy of SAR446268\,
  an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Ag
 ed 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1\nEs
 timated primary completion: 28 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sar446268#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844214
URL:https://assetmemo.bio/drug/sar446268#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848506-10786@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT04848506)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: Open-label Extension Study to Evaluate the Long-term Safety and To
 lerability of Aficamten in Adults With HCM\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aficamten
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048
 48506
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880770-1043@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Redemplo (Plozasiran): Phase 3 readout est. (NCT06880770)
DESCRIPTION:Redemplo (Plozasiran)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at 
 Risk of Acute Pancreatitis\nEstimated primary completion: March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/plozasiran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06880770
URL:https://assetmemo.bio/drug/plozasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372145-7074@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tolebrutinib: Phase 3 readout est. (NCT06372145)
DESCRIPTION:Tolebrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Investigate Long-term Safety and Tolerability of Tolebrutinib in Particip
 ants With Multiple Sclerosis.\nEstimated primary completion: 30 April 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tolebrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06372145
URL:https://assetmemo.bio/drug/tolebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184931-1@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184931)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: An Induction Stu
 dy to Investigate the Efficacy and Safety of Duvakitug in Participants Wit
 h Moderately to Severely Active Crohn's Disease\nEstimated primary complet
 ion: 14 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duv
 akitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07184931
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286214-5897@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290604
DTEND;VALUE=DATE:20290605
SUMMARY:Sarilumab: Phase 3 readout est. (NCT07286214)
DESCRIPTION:Sarilumab\, phase 3.\nStudy: Sarilumab Efficacy and Safety in A
 dults With Early Polymyalgia Rheumatica\nEstimated primary completion: 4 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07286
 214
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688213-779@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:SAR448851: Phase 2 readout est. (NCT07688213)
DESCRIPTION:SAR448851\, phase 2\, Alzheimer's Disease.\nStudy: A Study to I
 nvestigate the Safety and Effectiveness of SAR448851 in Participants With 
 Early Alzheimer's Disease\nEstimated primary completion: 31 July 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sar448851#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07688213
URL:https://assetmemo.bio/drug/sar448851#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285460-10760@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Qfitlia (Fitusiran): Phase 3 readout est. (NCT07285460)
DESCRIPTION:Qfitlia (Fitusiran)\, phase 3.\nStudy: A Study to Investigate t
 he Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 
 1 to Less Than 12 Years With Hemophilia A or B\nEstimated primary completi
 on: 4 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fi
 tusiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07285460
URL:https://assetmemo.bio/drug/fitusiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184944-1@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184944)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: A Maintenance St
 udy to Investigate the Efficacy and Safety of Duvakitug in Participants Wi
 th Moderately to Severely Active Crohn's Disease\nEstimated primary comple
 tion: 13 August 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07184944
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412470-7194@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Frexalimab: Phase 2/3 readout est. (NCT07412470)
DESCRIPTION:Frexalimab\, phase 2/3.\nStudy: A Study to Investigate the Effi
 cacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidne
 y Transplantation\nEstimated primary completion: 15 August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07412470
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771439-1886@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Belumosudil: Phase 3 readout est. (NCT07771439)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Belumosudil Compared With Be
 st Available Therapy in Participants Aged 12 Years or Older With Chronic G
 raft-versus-host Disease\nEstimated primary completion: 14 September 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07771439
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859099-11341@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291003
DTEND;VALUE=DATE:20291004
SUMMARY:Riliprubart: Phase 3 readout est. (NCT06859099)
DESCRIPTION:Riliprubart\, phase 3.\nStudy: Long-term Safety and Efficacy St
 udy of Riliprubart in Participants With CIDP\nEstimated primary completion
 : 3 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ril
 iprubart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06859099
URL:https://assetmemo.bio/drug/riliprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190209-1424@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291127
DTEND;VALUE=DATE:20291128
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07190209)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: Efficacy\, Safety\, and Tolerability Study of Lunsekimig Compared W
 ith Placebo in Adult Participants With Inadequately Controlled Chronic Obs
 tructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenoty
 pe\nEstimated primary completion: 27 November 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07190209
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190222-1424@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291127
DTEND;VALUE=DATE:20291128
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07190222)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: Efficacy\, Safety\, and Tolerability Study of Lunsekimig Compared W
 ith Placebo in Adult Participants With Inadequately Controlled Chronic Obs
 tructive Pulmonary Disease (COPD)\, Characterized by an Eosinophilic Pheno
 type\nEstimated primary completion: 27 November 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07190222
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412666-10786@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT06412666)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: A Study to Evaluate the Effect of Aficamten in Pediatric Patients 
 With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).\nEstimate
 d primary completion: January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/aficamten#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06412666
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927140-1714@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300114
DTEND;VALUE=DATE:20300115
SUMMARY:Venglustat (GZ/SAR402671): Phase 3 readout est. (NCT07927140)
DESCRIPTION:Venglustat (GZ/SAR402671)\, phase 3\, Gaucher Disease.\nStudy: 
 The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric 
 Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)\nEstim
 ated primary completion: 14 January 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venglustat-gz-sar402671#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07927140
URL:https://assetmemo.bio/drug/venglustat-gz-sar402671#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-3136@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Isatuximab: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Isatuximab in 
 Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Mu
 ltiple Myeloma\nEstimated primary completion: 14 October 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609239-1424@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310120
DTEND;VALUE=DATE:20310121
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06609239)
DESCRIPTION:lunsekimig\, phase 2\, Asthma.\nStudy: Long-term Safety and Eff
 icacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asth
 ma\nEstimated primary completion: 20 January 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06609239
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930624-7194@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310516
DTEND;VALUE=DATE:20310517
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07930624)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: A Study to I
 nvestigate Long-term Safety and Tolerability of Frexalimab in Participants
  With Multiple Sclerosis\nEstimated primary completion: 16 May 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07930624
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793409-1424@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310723
DTEND;VALUE=DATE:20310724
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07793409)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig
  in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)\n
 Estimated primary completion: 23 July 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07793409
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910685-11344@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Elenestinib: Phase 2/3 readout est. (NCT04910685)
DESCRIPTION:Elenestinib\, phase 2/3\, Systemic Mastocytosis.\nStudy: (HARBO
 R) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Pati
 ents With Indolent Systemic Mastocytosis\nEstimated primary completion: 30
  September 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elen
 estinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04910685
URL:https://assetmemo.bio/drug/elenestinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01736592-5247@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20330829
DTEND;VALUE=DATE:20330830
SUMMARY:SAR422459: Phase 2 readout est. (NCT01736592)
DESCRIPTION:SAR422459\, phase 2.\nStudy: Phase I/II Follow-up Study of SAR4
 22459 in Patients With Stargardt's Macular Degeneration\nEstimated primary
  completion: 29 August 2033. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sar422459#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT01736592
URL:https://assetmemo.bio/drug/sar422459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923305-1477@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20350510
DTEND;VALUE=DATE:20350511
SUMMARY:rilzabrutinib: Phase 2/3 readout est. (NCT07923305)
DESCRIPTION:rilzabrutinib\, phase 2/3.\nStudy: Phase 2 and 3 Placebo Contro
 lled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to 
 Evaluate Efficacy\, Safety\, and Tolerability\nEstimated primary completio
 n: 10 May 2035. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilza
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07923305
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
